What clinicians say about clinical trials, and why.
How oncologists read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question. Each report is a two-minute summary for you, the analysis behind every finding, and evidence your AI agent can order and query, with every view linked to its source.
Explore the report previews
| Trial | Indication | Phase | Statements | Sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| LIBERTAS NCT05884398 · Janssen Research & Development, LLC | metastatic castration-sensitive prostate cancer | Phase 3 | 813 | 56 | Deep | Nov 3, 2026 | Preview |
| ARASTEP NCT05794906 · Bayer | high-risk biochemical recurrence of prostate cancer | Phase 3 | 193 | 19 | Standard | Nov 3, 2026 | Preview |
| COXEN NCT02177695 · SWOG Cancer Research Network | localized muscle-invasive bladder cancer | Phase 2 | 406 | 62 | Deep | Nov 3, 2026 | Preview |
| DAWN-303 NCT07522073 · Incyte Corporation | previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma | Phase 3 | 58 | 15 | Focused | Nov 3, 2026 | Preview |
| DeLLphi-309 NCT06745323 · Amgen | small cell lung cancer | Phase 2 | 206 | 39 | Standard | Nov 3, 2026 | Preview |
| DESTINATION 2 NCT06638541 · Royal Marsden NHS Foundation Trust | prostate cancer | Not applicable | 172 | 16 | Standard | Nov 3, 2026 | Preview |
6 of 103 reports
# What Erudio is and how to query it
curl https://www.erudio.com/llms.txt
# Every report, with counts, version and links
curl https://www.erudio.com/catalog.json
# One report as JSON or Markdown
curl https://www.erudio.com/reports/{slug}.json{
"mcpServers": {
"erudio": { "url": "https://mcp.erudio.com/mcp" }
}
}
# then ask your agent:
# search_reports({ "drug": "ifinatamab-deruxtecan" })- 103 published reports
- any listed oncology trial built within 24 hours
- weekly updates
- every statement source-linked
Check our work before you buy.
What comparative durability, survival, pulmonary-safety and administration evidence would justify I-DXd's place among available options, and what referral or patient-support needs accompany those choices?
- 01Clinicians qualify favorable tolerability assessments with ILD vigilance; one poster calls the therapeutic index “untenable”
- 02Clinicians want randomized confirmation; posters caution that withdrawal does not identify the precise regulatory shortcoming
- 03Clinicians welcome response activity, while one early reply disputes whether PFS and OS are promising
- 04One interview presents brain activity as potentially treatment-changing, with a small subgroup explicitly qualified
The whole report is free. Trace any finding to the podcast, video or post it came from.
The executive summary, the analysis of every finding, and the verified statements behind them, each linked to its source.
- Meeting prepSpeaker briefs for an MSL visitSee the answer
- Readout reactionA one-page brief for the VPSee the answer
- Congress briefingA pre-congress briefingSee the answer
- Advisory boardsAn advisory board agendaSee the answer
- Competitive contextA comparison briefSee the answer
- Evidence gapsAn evidence-gap listSee the answer
- Launch and access signalsAccess and readiness signalsSee the answer
- Education needs assessmentQuestions for the education grants teamSee the answer
One trial, read three ways.
Every report has the same three parts, for you, for the colleagues you forward it to, and for your AI agent. Enterprise MCP adds the whole commentary corpus for your organization's agents.
Executive summary
The two-minute read: how the clinicians who discussed the trial read it, where they differ, and the open question for Medical Affairs. A PDF to forward.
Detailed analysis
The reasoning, disagreements, qualifications and counterviews behind each finding, to read in your browser.
Structured evidence
Every verified statement with its speaker, date, short quote and link, as JSON and through the Erudio MCP, so your agent can check any finding.
Follow a trial with weekly updates: when the commentary changes a finding you get a new edition and a note of what changed, and when nothing changes you get a dated note that the report is current. See everything a report holds, including each speaker's CMS-reported financial relationships.
A single report, agent included
Buy the current edition, or follow a trial with 3, 6 or 12 months of weekly updates, with no enterprise contract. Trials without a report are built within 24 hours of your order.
Enterprise MCP, the whole corpus
Your agents search all the clinician podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses. Ask “prep me for my meetings with these five oncologists” and get sourced answers.
What you have today, and what Erudio adds
Most teams already pay for some of these. Erudio fills the gap between them: the clinician's own reasoning about a trial, in public, with the source.
| You have | It gives you | Erudio adds |
|---|---|---|
| Your own analyst or Medical Director | Judgment and context, one trial at a time, as time allows. | Hours of podcasts, video and posts already read and sorted by finding, each statement linked to its passage, so their time goes to judgment. |
| KOL and HCP databases | Who a clinician is: affiliations, publications, trials. | What they said about a trial, where and when, with their reasoning. Use both. |
| Social listening | Mentions and sentiment, mostly from short posts. | Long-form podcasts and video as well as X, with clinical views kept apart from reactions. |
| Field medical insights | What your MSLs heard in private conversations. | What clinicians say in public, each statement attributed to a named speaker, with optional verified speaker identities to check who said what. It complements your field insights and never ingests them. |
| Agencies and congress reports | One question per project, in weeks. | A report on any listed trial within 24 hours, with every source linked, plus weekly updates. With Enterprise MCP, your agent asks the next question itself. |
| General AI chat | Fast answers with uncertain sources. | Every statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps. |
Public sources only. Every statement linked. Every edition versioned, with corrections in the open.
- Every report keeps what clinicians said apart from what the primary evidence establishes, and never turns commentary into an efficacy verdict or a consensus. Methods
- Reports state what they do not cover, on every page
- Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
- Co-founder Audun Utengen has published research with clinicians in BMJ, JAMA Oncology and the European Heart Journal
- Security-only SOC 2 Type II report, available under NDA. Non-promotional: no efficacy verdicts, consensus scores or rankings. Trust center